Measles is spreading across the U.S.
Children who haven't gotten the MMR vaccine are most at risk. The vaccine is the best way to protect yourself and loved ones. Measles: What to Know
Press Releases
Transition of RSV Vaccine Ordering to NCIREffective Tuesday, October 21, 2025, the NCIP is transitioning RSV vaccine ordering from the Smartsheet Request Form to the North Carolina Immunization Registry (NCIR).Note: All orders previously placed through Smartsheet have been processed.Inventory ManagementPlease monitor your inventory and maintain sufficient stock to meet the needs of Vaccines for Children (VFC)-eligible patients throughout the 2025–2026 respiratory season.
The purpose of this memo is to provide important details regarding the upcoming holiday vaccine shipping schedule for the Vaccines for Children (VFC) and the 317 Vaccines for Adults (317 VFA) programs.
Immunization Compliance Reporting for Colleges and Universities Memo (PDF)
Dear Local Health Departments,On Oct. 6, 2025, the Acting CDC Director approved the Advisory Committee on Immunization Practices (ACIP) COVID-19 vaccine recommendations. The CDC has updated its adult and child immunization schedules to apply individual-based decision-making to COVID-19 vaccination for 6 months and older, after consultation with a health care provider.
North Carolina Vaccines for Children (VFC) providers can now order the pentavalent meningococcal (A,B,C,W, and Y) vaccine, PENMENVY™ (NDC 58160-757-15) via NCIR for administration to their VFC-eligible adolescents (ages 10 through 18 years).
The purpose of this memo is to provide North Carolina Immunization Program (NCIP) providers with the latest information on the 2025-2026 COVID-19 vaccine. Please take time to carefully review this memo in full. COVID-19 vaccines for VFC-eligible patients are now available to order through NCIR.
Download the 2025 Annual Child care Immunization Report Memo
This email is to inform you that the North Carolina Immunization Program (NCIP) has opened applications for birthing hospitals interested in participating in the replacement model for birth dose Hepatitis B and RSV.
The purpose of this email is to inform VFC-enrolled providers that the RSV monoclonal antibody product clesrovimab (trade name ENFLONSIA™ manufactured by Merck) is now available for ordering. VFC doses will begin shipping after Oct. 2, 2025.Clesrovimab UseClesrovimab is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants under 8 months of age who are born during or entering their first RSV season and who are not protected through maternal RSV vaccination.
Download The 2025 LHD Annual Immunization Assessment MemoThe purpose of this memo is to remind local health department (LHD) staff about the upcoming 2025 Annual Immunization Assessment. This assessment will review NCIR records of children, 24 through 35 months old, who are labeled "active" in NCIR under the LHD site, as well as all children that live in the county.